IN-VITRO AND IN-VIVO STUDIES ON THE ACTION OF BW502U83, AN ARYLMETHYLAMINOPROPANEDIOL

BW502U83, an arylmethylaminopropanediol (AMAP), showed to be partially cross resistant in a P-glycoprotein-positive and in a P-glycoprotein- negative, doxorubicin-resistant cell line, while no cross-resistance w as noticed in a cisplatin-resistant cell line. Interstrand cross-links were not observed, but BW502U83 induced extensive DNA strand breaks. In a feasibility study the effect of intra-arterially BW502U83 was tes ted. One patient with a hepatocellular carcinoma showed partial remiss ion and signs of a tumor lysis syndrome, another patient with a hepato cellular carcinoma improved clinically. A patient with soft tissue sar coma had stable disease. Transient increase in SGOT, SGPT and LDH were observed, but no systemic side effects.